SPRUCE BIOSCIENCES, INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that SPRUCE BIOSCIENCES, INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $0 | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | $4.91M | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | $10.09M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $0 | Mar 18, 2024 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($38.97M) | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | ($53.04M) | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | ($47.92M) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | ($46.18M) | Mar 18, 2024 |
| FY2022 | Dec 31, 2021 | ($42.29M) | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | ($29.54M) | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | ($13.09M) | Mar 22, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($36.51M) | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | ($56.15M) | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | ($51.99M) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | ($47.28M) | Mar 18, 2024 |
| FY2022 | Dec 31, 2021 | ($42.07M) | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | ($29.42M) | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | ($13.11M) | Mar 22, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $19.52M | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | $46.42M | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | $49.43M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $35.20M | Mar 18, 2024 |
| FY2022 | Dec 31, 2021 | $30.70M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $23.85M | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | $10.82M | Mar 22, 2021 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($33.33M) | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | ($55.96M) | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | ($33.28M) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | ($41.68M) | Mar 18, 2024 |
| FY2022 | Dec 31, 2021 | ($35.88M) | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | ($27.52M) | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | ($12.62M) | Mar 22, 2021 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $0 | Apr 15, 2025 |
| FY2024 | Dec 31, 2023 | $7.0K | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $8.0K | Mar 18, 2024 |
| FY2022 | Dec 31, 2021 | $93.0K | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $74.0K | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | $4.0K | Mar 22, 2021 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $53.02M | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | $45.21M | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | $103.95M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $85.65M | Mar 18, 2024 |
| FY2022 | Dec 31, 2021 | $126.49M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $162.88M | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | $4.69M | Mar 22, 2021 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $10.51M | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | $16.39M | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | $27.44M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $17.16M | Mar 18, 2024 |
| FY2022 | Dec 31, 2021 | $15.12M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $13.46M | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | $7.52M | Mar 22, 2021 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $42.52M | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | $28.82M | Mar 9, 2026 |
| FY2025 | Dec 31, 2023 | $76.51M | Mar 9, 2026 |
| FY2024 | Dec 31, 2022 | $68.49M | Apr 15, 2025 |
| FY2023 | Dec 31, 2021 | $111.37M | Mar 18, 2024 |
| FY2022 | Dec 31, 2020 | $149.43M | Mar 16, 2023 |
| FY2021 | Dec 31, 2019 | ($30.64M) | Mar 14, 2022 |
| FY2020 | Dec 31, 2018 | ($17.80M) | Mar 22, 2021 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($289.23M) | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | ($250.27M) | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | ($197.23M) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | ($149.31M) | Mar 18, 2024 |
| FY2022 | Dec 31, 2021 | ($103.13M) | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | ($60.84M) | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | ($31.30M) | Mar 22, 2021 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $48.91M | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | $38.75M | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | $96.34M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $24.49M | Mar 18, 2024 |
| FY2022 | Dec 31, 2021 | $42.75M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $157.15M | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | $3.92M | Mar 22, 2021 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $1.84M | Apr 15, 2025 |
| FY2023 | Dec 31, 2023 | $3.71M | Mar 18, 2024 |
| FY2022 | Dec 31, 2022 | $5.64M | Mar 16, 2023 |
| FY2021 | Dec 31, 2021 | $4.88M | Mar 14, 2022 |
| FY2021 | Dec 31, 2020 | $4.48M | Mar 14, 2022 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (50) | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | (96) | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | (1) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | (1) | Mar 18, 2024 |
| FY2022 | Dec 31, 2021 | (1) | Mar 16, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (50) | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | (96) | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | (1) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | (1) | Mar 18, 2024 |
| FY2022 | Dec 31, 2021 | (1) | Mar 16, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1.37M | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | 563,042 | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | 41.03M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | 23.60M | Mar 18, 2024 |
| FY2022 | Dec 31, 2021 | 23.49M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | 23.26M | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | 764,408 | Mar 22, 2021 |